Taitacept for refractory or recurrent autoimmune encephalitis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older
- You have been diagnosed with autoimmune encephalitis (with anti-NMDAR or anti-LGI1 antibodies) and your symptoms started within the last 9 months
- Your condition did not improve with steroids and rituximab or other immune-suppressing drugs, or it came back after treatment
- You are not pregnant, breastfeeding, or planning to have children during the trial
- You do not have other autoimmune diseases (like lupus or rheumatoid arthritis) or active infections (like tuberculosis or shingles)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
This trial tests a drug called efgartigimod, which may help people with anti-NMDA receptor encephalitis, a condition where the immune system attacks the brain. The study aims to see if it can improve symptoms when added to standard steroid treatment.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests whether rituximab, a medication that calms the immune system, can help people with certain nerve or brain conditions linked to a specific antibody. It aims to reduce symptoms or prevent the disease from getting worse.
This study collects health information from people with autoimmune encephalitis, a condition where the body's immune system attacks the brain. It aims to understand the disease better, and if you have seizures from it, you can join a special epilepsy part.
This trial tests a low-dose medication called blinatumomab (a type of immunotherapy) to see if it can help people with severe, treatment-resistant autoimmune encephalitis or autoimmune cerebellitis. It aims to calm the immune system's attack on the brain, potentially improving symptoms when standard treatments haven't worked.
Hear when a new Anti-N-Methyl-D-Aspartate Receptor Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.